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Summary: The article presents a study results on the dynamics of lipid spectrum under the influence of 
combination regimens of lipid-lowering therapy (statin + fibrate and a statin + ω-3 PUFA). The data 
shown a significant lipid-lowering effect of combinated therapy  by fibrate with a statin on all the 
atherogenic fractions. Integrated application of statin with ω-3 PUFA allowed not only to reduce the 
atherogenic lipid fractions, but also achieve a higher level of HDL. The results indicate a greater 
effectiveness of the medication complex as compared with statin monotherapy, as well as the need for a 
differentiated approach to lipid-corrective therapy based on blood lipid fractions baseline.  
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The main cause of ischemic heart disease   (IHD) is atherosclerosis (AS) due to 
dyslipidemia IIa, IIb or III type by Fredrickson [1]. According to modern concepts, 
hypercholesterolemia, and especially an increasing of serum low-density lipoprotein 
(LDL) level, is a one of the most important factors in the development of cardiovascular 
disease [2, 3].  
However, modern  researching datas on the field of Lipidology shows that high 
cholesterol and increased LDL are not the only leading  mechanisms, which  is the trigger 
of atherogenesis. The convincing data, that obtained in last time, show that the decrease of 
high-density lipoprotein (HDL) involved in the transport of cholesterol (LDL) from tissues 
back to the liver, promotes to the atherogenicity of the blood and become an independent 
risk factor for coronary heart disease [4].  
The degree of AS risk is increased if an increase of LDL cholesterol and low levels 
of HDL-C connect with the hypertriglyceridemia [5, 6]. With this in mind, the choice of 
250 
lipid-lowering drugs important is their ability to correct the levels of triglycerides (TG) 
and HDL.  
At present the correction of LDL with statins is considered modern clinical protocols 
as a key element of the strategy to reduce the risk of coronary heart disease (primary 
prevention) or cardiovascular events (secondary prevention). [5]  At the same time, in 
accordance with European and Ukrainian recommendations for the prevention of AS in 
patients with increased cardiovascular risk should strive to achieve optimal levels of blood 
lipids [5]. However, after statin monotherapy, even at maximum doses, there is often a 
problem of residual cardiovascular risk, which is estimated by various authors at the level 
of 30-70% [7, 8]. Also, the effect of statins on TG and HDL not so great as in other 
atherogenic fraction. More important is the effect expressed in other classes of lipid-
lowering drugs, such as fibrates and a ω-3 polyunsaturated fatty acids (PUFA) [5, 9, 10].  
It is evident that a combination of small doses of drugs from different groups can be 
not only more efficient but also better tolerated than vysokodozovaya monotherapy. 
In this regard, actual is now a comparative study of the efficacy of different combined 
therapy strategies. And if research on the issue of comparing combination therapy with 
statin monotherapy, appeared only the last years and, as a consequence, very few in 
number, the comparative studies of combinations of lipid-lowering drugs, we have not 
found.  
Objective: To compare the efficiency of the combination regimens of lipid-lowering 
therapy (statin + fibrate and a statin + ω-3 PUFA).  
Materials and Methods: 
The subjects of the study were 71 patients with stable angina I-III functional class 
(FC), who was treated at the cardiology department of the Military Medical Clinical 
Centre of South region and therapeutic department of the Yuzhnyi city hospital  (Odessa 
region). The diagnosis of stable angina was esteblished  in accordance with the 
recommendations of the Association of Cardiologists of Ukraine (2007),and  the 
classification of the Canadian Cardiology Society of [6].  
Inclusion criteria: signed patient's informed  consent form and verified diagnosis of  
stable angina pectoris I - III FC.  
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Exclusion criteria: acute coronary syndrome, chronic heart failure above FC IV by 
NYHA and severe comorbidities (decompensation of chronic diseases, septic status, 
cancer, hematological diseases, etc.).  
Patients have been divided for three groups: 
Group I - 25 patients (control group). Treatment by the standard complex regimens for the 
treatment of stable angina pectoris (beta-blockers, aspirin, ACE inhibitors, nitrates, statins 
- atorvastatin in a daily dose of 20 mg). 
Group II - 25 patients. Standart complex regimen swith atorvastatin (daily dose 10 mg) 
plus fenofibrate (Tricor in a daily dose 145 mg) for the entire of observation period. 
Group IIІ - 21 patients. Standart complex regimen swith atorvastatin (daily dose 10 mg) 
plus ω-3 PUFA (omega-3 vitrum cardio,  daily dose - 2 g). 
 The treatment groups were broadly representative of the age ( Gr. I:63,2±2,6 y.o,  
Gr.: II 62,1±2,49 y.o., Gr.III: 59,17±2,63 y.o.) and angina range (Gr. I:1,91±0,15 FC, Gr.II: 
1,87±0,12 FC and Gr.III: 2,25±0,18 FC). On average, the duration of treatment was 6-8 
weeks. 
 Blood samples from the all patients were collected before and after treatment from 
a peripheral vein.  We analyzed the following parameters: total cholesterol (TC), 
triglycerides, LDL, VLDL, HDL, atherogenic index (AI). Components of lipid spectrum 
(total cholesterol, triglycerides, LDL, VLDL, HDL) were studied on an automatic 
biochemical analyzer Cobas Mira Plus (Switzerland) using reagent kits firm 
"BIOLATEST" (Czech Republic). The content of VLDL and AI was determined by the 
following formulas:   
VLDL = total cholesterol - HDL cholesterol - LDL cholesterol                                                       
AI = total cholesterol - HDL cholesterol / HDL-C             
 
The resulting material was processed using the statistical program «STATISTICA 
6.0». The data were processed by the method of variation statistics using the Student t-test. 
Results are presented as mean and SEM (M ± m). The differences between the studied 
parameters were considered statistically significant between p <0.05.  
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Results and discussion:  
The first results showed that in all groups of patients the mean values of atherogenic 
fractions (total cholesterol, triglycerides, LDL, VLDL, IA) were much higher than normal, 
which coincides with the opinion of other authors [11]. The results obtained under the 
influence of a complex with standard medical atorvastatin are shown in Table 1.  The table 
shows a significant decrease  of more atherogenic lipid fractions: TC and LDL (p = 0,002 
and p = 0,0003). However, necessary to emphasize that the decrease of this fraction did 
not reach the required level for patients with coronary heart disease [5], and, accordingly, 
require further decline.  
Thus, as a result of treatment with standard drugs complex with atorvastatin, even 
though they were marked by a significant positive change in the attitude of total 
cholesterol and LDL, these indicators not achieved target levels for patients with coronary 
artery disease, and make a difference in the treatment of dyslipidemia on indicators such as 
HDL, TG and EA did not succeed.  
 
Table 1- Dynamics of the blood lipid spectrum under the influence of 
standard medical complex with the atorvastatin  
Parameter 
Before the 
treatment 
After the 
treatment 
p1 
Total cholesterol (mmol / L)  6,07±0.24 5.26±0.24 0.002 
LDL (mmol / L)  3.76±0.29 2.99±0.22 0.0003 
VLDL (mmol / L)  1.01±0.14 1.2±0.18 0.1 
TG (mmol / L)  1.72±0.12 1.93±0.27 0.47 
HDL (mmol / l)  1.3±0.15 1.07±0.09 0.2 
IА (un.) 5.1±0.72 4.68±0.49 0.55 
 
These data show that the proposed scheme is given a positive impact on the main 
range of blood atherogenity of patients with coronary artery disease, but has an 
insignificant effect on a number of factions lipid profile, and therefore need to be 
optimized.  
Considering the data obtained by us about the weak effect of statins on some lipid 
fractions, as well as the authors report about the a more expressed effect of fibrates on TG 
and HDL-C [5, 12], the expected results of the combined treatment with statins with 
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fibrates applied a more pronounced positive effect on all indicators of lipid metabolism. 
Results are shown in Table. 2.  
 
 
 
 
 
 
Table. 2 - Dynamics of blood lipid profile under the standard medication complex - 
combination of atorvastatin and fenofibrate  
 
Parameter Group I 
 standart  therapy 
Group II  
standart  therapy 
+ atorvastatin and fenofibrate  
 
p1-2 
before the 
treatment 
after the 
treatment 
p1 before the 
treatment 
after the 
treatment 
p2 
Total cholesterol 
(mmol/L)  
6,07±0.24 5.26±0.24 0.002 6.44±0.24 5.26±0.17 0.0001 0.27 
LDL (mmol / L)  3.76±0.29 2.99±0.22 0.0003 3.53±0.26 2.98±0.26 0.045 0.46 
VLDL (mmol/L)  1.01±0.14 1.2±0.18 0.15 1.54±0.17 0.97±0.14 0.009 0.003 
TG (mmol/L)  1.72±0.12 1.93±0.27 0.47 2.63±0.16 1.48±0.10 0.0001 0.0003 
HDL (mmol/l)  1.3±0.15 1.07±0.09 0.2 1.25±0.10 1.28±0.09 0.69 0.18 
IА (un.) 5.1±0.72 4.68±0.49 0.55 4.97±0.49 3.42±0.30 0.0004 0.16 
 
As seen from Table 2, the use of combined treatment (standard complex with 
inclusion of statins and fibrates) achieved a significant reduction of total cholesterol 
concentration (6,44 ± 0,24) mmol / L to (5,26 ± 0,17) mmol / l (p = 0,0001), more 
pronounced than in the control group. Also, a significant decrease was observed in LDL 
cholesterol (p = 0.04), although significant intergroup differences are controlled by these 
parameters were observed (p = 0.27 and p = 0.46).  
The most distinctive in this group of patients was significant (p = 0,0001 and p = 
0.009) reduction TG levels (2,40 ± 0,18 to lech. And 1,43 ± 0,08 after lech., P = 0,0001 ) 
and VLDL (1,54 ± 0,17 to lech. and 0,97 ± 0,14 after lech., p = 0.009) were significantly 
different from the control group (p = 0.003 and p = 0.003). In accordance with the decline 
in the major atherogenic fractions also decreased significantly IA (p = 0,0004) - from 4,97 
± 0,49 to 3,42 ± 0,30, preferably by reducing the total cholesterol, while the decrease in 
the control group IA was not statistically significant (p = 0.55).  
In difference from published data about the  increasing of HDL cholesterol by an 
average of 10.5% under the fibrates [5, 12], we did not mark any positive dynamics of 
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their level in this group of patients (1,28 ± 0,09 to lech. 1 and , 27 ± 0,07 after lech.). In 
summary, we can conclude that it is a significant lipid-lowering effect of fenofibrate in 
combination with a statin at a daily dose of 10 mg, noting the marked effect on TG and 
virtually no effect on HDL.  
A substantial effect on TG and HDL and also tend to ω-3 PUFAs [10], which 
allowed expect a more pronounced efficacy in all lipid fractions. The results are shown in 
Table. 3.  
Table 3 - Dynamics of lipid profile under the influence of a standard medical complex with the 
inclusion of atorvastatin and ω-3 PUFA  
 
Parameter Group I 
 standart  therapy 
Group III 
standart  therapy 
+ atorvastatin and ω-3 PUFA  
 
p1-3 
before the 
treatment 
after the 
treatment 
p1 before the 
treatment 
after the 
treatment 
p3 
Total cholesterol 
(mmol/L)  
6,07±0.24 5.26±0.24 0.002 6,14±0,25 5,16±0,20 0,006 0.6 
LDL (mmol / L)  3.76±0.29 2.99±0.22 0.0003 3,47±0,33 2,14±0,22 0,002 0.08 
VLDL (mmol/L)  1.01±0.14 1.2±0.18 0.15 1,32±0,13 0,84±0,08 0,001 0.0002 
TG (mmol/L)  1.72±0.12 1.93±0.27 0.47 2,90±0,29 1,83±0,17 0,001 0.001 
HDL (mmol/l)  1.3±0.15 1.07±0.09 0.2 1,38±0,16 2,23±0,33 0,005 0.001 
IА (un.) 5.1±0.72 4.68±0.49 0.55 4,21±0,71 1,73±0,31 0,0001 0.02 
 
The table shows that, despite the absence of a significant between-group differences 
with the control group (p = 0.6) under the influence of combined treatment with statins, 
and the inclusion of ω-3 PUFA  total cholesterol was significantly reduced from (6,14 ± 
0,25) mmol / L to (5,16 ± 0,20) mmol / L (p = 0,006). There was also a significant 
reduction in LDL cholesterol (p = 0.002), VLDL (p = 0.001), and triglycerides (p = 0.001) 
were significantly different from the control group (p = 0.08, p = 0.0002, p = 0.001). 
Synchronously with the reduction of atherogenic fractions decreased by 59.0% and IA - 
from 4,21 ± 0,71 to 1,73 ± 0,31 (p = 0,0001), were also significantly different from the 
control group (p = 0, 02).  
In contrast to the other groups was statistically significant (p = 0.005) positive trend 
levels of HDL - from (1,38 ± 0,16) mmol / L to (2,23 ± 0,33) mmol / L, significantly 
different from the control group (p = 0.001). Based on the foregoing, it can be concluded a 
significant lipid-lowering effect combination ω-3 fatty acids with a statin in a daily dose of 
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10 mg, expressed in relation to both of atherogenic and antiatherogenic fraction.  
After receiving of information about a positive effect on the lipid profile of lipid-
lowering combinated herapy, the most interesting to compare the effectiveness of two of 
the studied combinations (Table 4)  
 
 
 
Table 4 - The dynamics of blood lipid profile under the  studied therapeutical combinations  
Parameter Group II 
standart  therapy+ 
atorvastatin and fibrate  
Group III 
standart  therapy+ 
atorvastatin and ω-3 PUFA  
 
p2-3 
before the 
treatment 
after the 
treatment 
p2 before the 
treatment 
after the 
treatment 
p3 
Total cholesterol 
(mmol/L)  
6.44±0.24 5.26±0.17 0.0001 6,14±0,25 5,16±0,20 0,006 0.55 
LDL (mmol / L)  3.53±0.26 2.98±0.26 0.045 3,47±0,33 2,14±0,22 0,002 0.04 
VLDL (mmol/L)  1.54±0.17 0.97±0.14 0.009 1,32±0,13 0,84±0,08 0,001 0.70 
TG (mmol/L)  2.63±0.16 1.48±0.10 0.0001 2,90±0,29 1,83±0,17 0,001 0.78 
HDL (mmol/l)  1.25±0.10 1.28±0.09 0.69 1,38±0,16 2,23±0,33 0,005 0.004 
IА (un.) 4.97±0.49 3.42±0.30 0.0004 4,21±0,71 1,73±0,31 0,0001 0.13 
 
As the table shows, the total cholesterol significantly decreased in both groups, 
however, are more pronounced degree of reduction was observed in the group with the  
fibrate, although significant between-group differences were observed (p = 0.55). LDL 
cholesterol decreased significantly in both groups, however, significantly greater in the 
group with the addition of ω-3 PUFAs, which confirms the accuracy of the intergroup 
difference (p = 0.04). VLDL concentration was significantly decreased in both groups, and 
the absence of inter-group differences (p = 0.70), the effect was more pronounced when 
using ω-3 PUFA (p = 0.001 vs. p = 0.009). In contrast, under the influence of fibrates 
observed greater effects on TG (p = 0.0001 vs. p = 0.001), but considering the significance 
of the results reliable intergroup difference was observed (p = 0.78).  
Thus, our data shows that statin monotherapy does not have a positive effect on 
HDL cholesterol, and there was even a mild tendency to deterioration (p = 0.2). Upon 
acceding to fibrate therapy, this orientation has disappeared and HDL levels remained 
unchanged (p = 0.69), and when used in treatment of ω-3 PUFA, the indicator changed its 
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focus to improve, and the difference was significant (p = 0.005) , and that led to a 
significant difference between groups II and III (p = 0.004). Based on the foregoing, it can 
be concluded about the impact of inadequate treatment in the control group at the level of 
HDL, the positive, but insufficient to normalize when joining a fibrate and a significant 
positive effect of ω-3 PUFA.  
Of the above data allows us to conclude not only to strengthen the effect of the 
studied hypolipidemic therapeutic complexes compared with statin monotherapy, but also 
of a "tropism" of  fibrates and ω-3 fatty acids to reducing of TG greater in fibrates, and ω-
3 PUFA – to reducing  of HDL. This, in turn, led to the dynamics and the integral index of 
the IA, who had only a slight downward trend in the group using statin monotherapy (p = 
0.55) and a significant decrease in the two groups with combined therapy (p = 0.0004 and 
p = 0 , 0001).  
Thus, these studies have shown that as a result of treatment with a standard 
medication complex using atorvastatin 20 mg daily, although it was observed a significant 
reduction in major atherogenic fractions (total cholesterol and LDL), they do not reach 
their target levels, and their effect on HDL , TG, VLDL and the EA complex in general was 
virtually ineffective.  
The combination of a fibrate with a statin had a significant lipid-lowering effect in 
respect of all atherogenic fractions, with the exception of HDL, and he was most 
pronounced with respect to total cholesterol and triglycerides. Under the influence of an 
integrated treatment with ω-3 PUFA has been achieved not only the reduction of all 
atherogenic lipid fractions, but also the best result in terms of the level of HDL. Based on 
the foregoing, one can conclude that a greater effectiveness of the combinations versus 
statin monotherapy. Moreover, given the different efficiencies combination regimens for 
individual fractions of lipids (triglycerides, HDL), requires a different approach in the 
assignment schemes lipid corrective therapy for patients based on baseline lipid levels.  
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